HK1171027A1 - 的調節或輔助蛋白的肽、組合物及它們的應用 - Google Patents

的調節或輔助蛋白的肽、組合物及它們的應用

Info

Publication number
HK1171027A1
HK1171027A1 HK12111361.4A HK12111361A HK1171027A1 HK 1171027 A1 HK1171027 A1 HK 1171027A1 HK 12111361 A HK12111361 A HK 12111361A HK 1171027 A1 HK1171027 A1 HK 1171027A1
Authority
HK
Hong Kong
Prior art keywords
hiv
regulatory
peptides
utilization
compositions
Prior art date
Application number
HK12111361.4A
Other languages
English (en)
Inventor
格雷戈里．艾倫．斯特洛夫
威爾遜．羅梅羅．卡帕羅斯-萬德雷
Original Assignee
派特塞爾有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0604920A external-priority patent/GB0604920D0/en
Priority claimed from GB0614260A external-priority patent/GB0614260D0/en
Application filed by 派特塞爾有限公司 filed Critical 派特塞爾有限公司
Publication of HK1171027A1 publication Critical patent/HK1171027A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK12111361.4A 2006-03-10 2012-11-09 的調節或輔助蛋白的肽、組合物及它們的應用 HK1171027A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0604920A GB0604920D0 (en) 2006-03-10 2006-03-10 Peptide sequences and compositions
GB0614260A GB0614260D0 (en) 2006-07-18 2006-07-18 Peptide sequences and compositions

Publications (1)

Publication Number Publication Date
HK1171027A1 true HK1171027A1 (zh) 2013-03-15

Family

ID=38232608

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12111361.4A HK1171027A1 (zh) 2006-03-10 2012-11-09 的調節或輔助蛋白的肽、組合物及它們的應用

Country Status (21)

Country Link
US (4) US20100055119A1 (zh)
EP (2) EP2392587B1 (zh)
JP (3) JP2009529570A (zh)
KR (1) KR20080106467A (zh)
CN (2) CN102443052B (zh)
AP (2) AP2015008680A0 (zh)
AU (1) AU2007226430B2 (zh)
BR (1) BRPI0708708A2 (zh)
CA (1) CA2645342A1 (zh)
DK (2) DK2004676T3 (zh)
EA (1) EA019733B1 (zh)
ES (2) ES2573105T3 (zh)
HK (1) HK1171027A1 (zh)
IL (2) IL193965A0 (zh)
MX (1) MX2008011520A (zh)
NO (1) NO20083576L (zh)
NZ (1) NZ570708A (zh)
PL (1) PL2392587T3 (zh)
SG (1) SG170092A1 (zh)
UA (1) UA97800C2 (zh)
WO (1) WO2007104932A2 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
EP3077417A1 (en) 2013-12-08 2016-10-12 Peptcell Limited Hiv antigens and antibodies and compositions, methods and uses thereof
WO2021094984A1 (en) 2019-11-14 2021-05-20 Aelix Therapeutics, S.L. Dosage regimens for vaccines

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330359A3 (en) 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of hiv-1 infection
DE4141970C2 (de) 1991-12-16 1998-02-19 Charite Med Fakultaet Kombinationsimpfstoff gegen AIDS, Bilharziose und Tuberkulose und Verfahren zu seiner Herstellung
WO1995010534A1 (en) 1993-10-14 1995-04-20 Seikagaku Corporation Polypeptide and anti-hiv agent prepared therefrom
KR100235849B1 (ko) 1993-10-19 1999-12-15 에가시라 구니오 HIV에 대한 면역응답을 유도할 수 있는 펩티드 및 그 펩티드를 함유하는 항 AIDS 예방, 치료제(Peptides Capable of Inducing Immune Response to HIV and Anti-AIDS Agent for Preventing and Curing AIDS)
US5843724A (en) * 1995-04-27 1998-12-01 Rutgers University Chimeric nucleic acids and proteins for inhibiting HIV-1 expression
WO1998052970A1 (en) * 1997-05-20 1998-11-26 St. Luke's-Roosevelt Hospital Vif-derived hiv protease inhibitors
PT2044950E (pt) 1997-09-18 2012-09-18 Univ Pennsylvania Cassetes de imunização adn de vif atenuadas para vacinas genéticas
US6228128B1 (en) 1997-11-10 2001-05-08 Charlotte Johansen Antimicrobial activity of laccases
US20030180314A1 (en) 1998-07-10 2003-09-25 Degroot Anne Immunogenic, cross-clade, HIV peptides
US20020182222A1 (en) * 1998-07-10 2002-12-05 Groot Anne De HIV vaccine candidate peptides
EP1155035A2 (de) * 1999-02-19 2001-11-21 Ulrich Schubert Synthetische peptide des regulatorischen virusproteins r (vpr) des humanen immundefizienzvirus typ 1 (hiv-1) und ihre verwendung
NO311807B1 (no) 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
WO2001024810A1 (en) * 1999-10-05 2001-04-12 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
CA2397998A1 (en) 2000-01-28 2001-08-02 Statens Serum Institut Hiv peptides and nucleic acids encoding them for diagnosis and control of hiv infection
NO314587B1 (no) 2000-09-04 2003-04-14 Bionor Immuno As HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
AU2002211524B2 (en) * 2000-10-04 2007-03-22 The Trustees Of The University Of Pennsylvania Highly expressible genes
EP1490396A4 (en) * 2001-03-01 2006-04-19 Us Gov Health & Human Serv IMMUNOGENIC HIV PEPTIDES AS REAGENTS AND AS VACCINES
RU2214274C2 (ru) 2001-08-16 2003-10-20 Государственное предприятие Институт иммунологии Федерального управления медико-биологических экстремальных проблем при МЗ РФ Иммуногенная композиция, содержащая химерный полипептид вич, полипептиды и тест-система для обнаружения антител к вич
WO2003015702A2 (en) * 2001-08-16 2003-02-27 The General Hospital Corporation Epitopes of human immunodeficiency virus-1
CA2357906A1 (en) 2001-09-28 2003-03-28 Institut Pasteur Identification of new cd8 epitopes from hiv-1 proteins with therapeutical and vaccinal properties against hiv infections
AU2003299134A1 (en) 2002-05-20 2004-04-23 The General Hospital Corporation Cytotoxic t-cell epitopes of hiv-1 virus
CA2500715A1 (en) 2002-10-03 2004-04-15 Epimmune, Inc. Hla binding peptides and their uses
EP1609107A4 (en) * 2003-03-28 2006-08-30 Idm Pharma Inc METHOD FOR IDENTIFYING OPTIMAL PEPTIDE PITOPARIANTS
KR20070028291A (ko) * 2003-09-17 2007-03-12 듀크 유니버시티 컨센서스／원형 면역원
ES2572132T3 (es) * 2004-08-17 2016-05-30 Roussy Inst Gustave Nef del VIH mutada para modular la inmunidad
AU2006283101B2 (en) 2005-08-23 2013-03-07 Beth Israel Deaconess Medical Center Polyvalent vaccine

Also Published As

Publication number Publication date
MX2008011520A (es) 2009-01-07
DK2004676T3 (en) 2017-02-20
US10034933B2 (en) 2018-07-31
AU2007226430B2 (en) 2013-08-29
JP2009529570A (ja) 2009-08-20
AU2007226430A1 (en) 2007-09-20
EP2392587A1 (en) 2011-12-07
US20100055119A1 (en) 2010-03-04
EP2004676B1 (en) 2016-11-16
EA200870342A1 (ru) 2009-02-27
NO20083576L (no) 2008-12-10
AP2015008680A0 (en) 2015-08-31
US20170281750A1 (en) 2017-10-05
WO2007104932A3 (en) 2007-11-22
CN102443052A (zh) 2012-05-09
CA2645342A1 (en) 2007-09-20
PL2392587T3 (pl) 2016-08-31
EA019733B1 (ru) 2014-05-30
US8992934B2 (en) 2015-03-31
ES2573105T3 (es) 2016-06-06
NZ570708A (en) 2011-12-22
EP2392587B1 (en) 2016-05-04
ES2616341T3 (es) 2017-06-12
CN102443052B (zh) 2014-12-31
BRPI0708708A2 (pt) 2011-06-07
CN104558126A (zh) 2015-04-29
EP2004676A2 (en) 2008-12-24
JP2013040172A (ja) 2013-02-28
UA97800C2 (uk) 2012-03-26
JP6422698B2 (ja) 2018-11-14
WO2007104932A2 (en) 2007-09-20
KR20080106467A (ko) 2008-12-05
CN104558126B (zh) 2020-02-14
DK2392587T3 (en) 2016-05-23
AU2007226430A2 (en) 2008-10-09
SG170092A1 (en) 2011-04-29
IL193965A0 (en) 2011-08-01
IL219544A0 (en) 2012-06-28
US20150182618A1 (en) 2015-07-02
AP3642A (en) 2016-03-16
JP2015007069A (ja) 2015-01-15
AP2008004609A0 (en) 2008-10-31
US20130039937A1 (en) 2013-02-14
US9675686B2 (en) 2017-06-13

Similar Documents

Publication Publication Date Title
HRP20181353T1 (hr) Tuberkulozni protein rv2386c, njegovi pripravci i upotreba
IL211762A0 (en) Pegylated opiods, compositions comprising the same and uses thereof
HK1221252A1 (zh) 限制的 肽及含有其的藥物組合物
IL195580A (en) L – fkbp polypeptides, preparations containing them, methods of preparation and use
IL204607A0 (en) Antibodies against osteoclast - related protein siglec - 15, compositions comprising the same and uses thereof
HK1127877A1 (en) Composition containing peptide as the active ingredient
IL195488A (en) Compounds, pharmaceuticals containing them and their uses
IL215603A0 (en) Human protein scaffold with controlled serum pharmacokinetics, compositions comprising the same and uses thereof
PL1913138T3 (pl) Sposoby wytwarzania pankreatyny w proszku o niskiej zawartości wirusa
IL186959A0 (en) Peptides and pharmaceutical compositions containing the same
IL205705A (en) Anti-flu antibodies, preparations containing them and their uses
IL197923A (en) Synthetic peptides, pharmaceutical preparations containing them and their uses
EP1976864A4 (en) NEW PEPTIDE AND ITS USE
IL187617A0 (en) Lkktet and/or lkktnt peptide compositions and methods
IL213043A0 (en) Lantibiotic carboxyamide derivatives, compositions comprising the same and uses thereof
IL185308A0 (en) Replikin peptides and uses thereof
GB0615635D0 (en) Immunogenic proteins and uses thereof
IL195525A0 (en) Replikin peptides and uses thereof
AP2008004512A0 (en) Bacteriocion inducer peptides
IL192824A (en) Peptide compounds, pharmaceuticals containing them and their use
IL213026A0 (en) TNA-a INHIBITING PEPTIDES, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF
HK1171027A1 (zh) 的調節或輔助蛋白的肽、組合物及它們的應用
ZA201006443B (en) Novel immunoregularory peptides,compositions and uses thereof
EP1910405A4 (en) PEPTIDES DERIVED FROM COMPLEMENT C3A AND APPLICATIONS THEREOF
IL205405A0 (en) Polypeptide compound, composition comprising the same and use thereof

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190309